samedan logo

 
 
spacer
home > pmps > autumn 2003 > editor's letter
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Editor's Letter

Picking up on the thread of my last editorial in the Summer issue of PMPS, it's painful to hear of the widespread shake-out going on throughout our industry. It seems that no organisation is so big that it can't get bigger through consolidation, without shedding layers of management or teams of skilled professionals, while none is so small that it lacks scope for becoming even leaner by downsizing. In the current climate of economic downturn, the bottom line is that accounts matter a great deal for the survival of businesses as the struggle continues to prune costs and aim for profitability.

Browsing the bumper crop of articles in the current and recent issues of PMPS, it appears that intellectual property (IP) has moved centre stage from the periphery of the

life science arena. In one corner are illegal counterfeiting practices, out to make a fast buck from pushing pirated versions of drugs by exploiting an unfulfilled consumer-driven demand (see page 109). In another there's a rising tide of products losing their patent protection and opening the way for cheaper generic versions, meeting the need for governments to contain costs (see page88). This leaves big pharma with the enormous task of replenishing its depleted development pipeline with innovative products from the biotech sector, while remaining saddled with the mounting costs of development. Overseeing this turf war is the regulatory gamekeeper barely able to keep up with the game (see page 72 on EU Clinical Trials Directive).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Editor of PMPS, Patricia Lobo rounds up current issues impacting on development and manufacturing in biotech and pharma.
spacer
Dr Patricia Lobo
spacer
spacer
spacer
Joanne Glover
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Element Materials Unveils One of the First and Largest Air Treatment Testing Facilities Designed to Support Indoor Space Public Health Air Quality

7,500ft3 Facility Now Open to Evaluate Aerosolized Product Efficacy; Reduce Airborne Organisms, Viral Particles
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement